News

Zipalertinib Displayed Promising Preliminary Antitumor Activity Among Patients With EGFR-Mutant NSCLC

07/24/2023

Stephanie Holland

According to results of a phase 1/2a study, zipalertinib demonstrated promising preliminary antitumor activity with acceptable safety among patients with heavily pretreated EGFR ex20ins-mutant NSCLC.

According to results of a phase...

07/24/2023

Oncology

News

Zipalertinib Displayed Promising Preliminary Antitumor Activity Among Patients With EGFR-Mutant NSCLC

07/24/2023

Stephanie Holland

According to results of a phase 1/2a study, zipalertinib demonstrated promising preliminary antitumor activity with acceptable safety among patients with heavily pretreated EGFR ex20ins-mutant NSCLC.

According to results of a phase...

07/24/2023

Oncology

News

Amivantamab Added to Chemotherapy Improves PFS Among Patients With Non-Small Cell Lung Cancer With EGFR Mutation

07/20/2023

Allison Casey

According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.

According to Janssen...

07/20/2023

Oncology

News

Amivantamab Added to Chemotherapy Improves PFS Among Patients With Non-Small Cell Lung Cancer With EGFR Mutation

07/20/2023

Allison Casey

According to Janssen...

07/20/2023

Oncology

News

Adjuvant Osimertinib Significantly Improved Overall Survival Among Patients With EGFR-Mutated NSCLC

07/10/2023

Stephanie Holland

According to final analysis results from the phase 3 ADAURA trial, adjuvant osimertinib significantly improved overall survival among patients with completely resected EGFR-mutated, stage 1B-2A NSCLC.

According to final analysis...

07/10/2023

Oncology

News

Adjuvant Osimertinib Significantly Improved Overall Survival Among Patients With EGFR-Mutated NSCLC

07/10/2023

Stephanie Holland

According to final analysis...

07/10/2023

Oncology

Videos

Adjuvant Osimertinib Improved Overall Survival for Patients With EGFR-Mutant NSCLC

06/19/2023

At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.

At the 2023 ASCO Annual Meeting,...

06/19/2023

Oncology

News

Concurrent Osimertinib and Chemotherapy for First-line EGFR-Mutated NSCLC

05/25/2023

A phase 2 trial confirmed the safety and efficacy of concurrent osimertinib and platinum-based chemotherapy in patients with previously untreated EGFR-mutated non-small cell lung cancer.

A phase 2 trial confirmed the...

05/25/2023

Oncology

News

Concurrent Osimertinib and Chemotherapy for First-line EGFR-Mutated NSCLC

05/25/2023

A phase 2 trial confirmed the safety and efficacy of concurrent osimertinib and platinum-based chemotherapy in patients with previously untreated EGFR-mutated non-small cell lung cancer.

A phase 2 trial confirmed the...

05/25/2023

Oncology

News

Osimertinib for Patients With Progressive EGFR-Mutated T790M-Negative NSCLC

04/21/2023

Derek Cowsert

Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.

Osimertinib demonstrated modest...

04/21/2023

Oncology

Recent News

FDA Alerts

FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors

10/18/2024

Stephanie Holland ;

Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...

Based on results from the...

10/18/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

FDA Approval

FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer

10/17/2024

Allison Casey ;

On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.

On October 15, 2024, the FDA...

10/17/2024

Oncology

News

Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML

10/15/2024

Amber Denham ;

According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...

According to phase 3 results...

10/15/2024

Oncology

FDA Approval

FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

10/10/2024

Allison Casey ;

The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA has approved inavolisib,...

10/10/2024

Oncology

News

Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis

10/10/2024

Amber Denham ;

Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.

Momelotinib was well-tolerated,...

10/10/2024

Oncology

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma

10/10/2024

Amber Denham ;

While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...

While allogeneic stem cell...

10/10/2024

Oncology

News

Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer

10/09/2024

Stephanie Holland ;

According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.

According to results from the...

10/09/2024

Oncology

Conference Coverage

Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer

10/09/2024

Stephanie Holland ;

According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.

According to interim analysis...

10/09/2024

Oncology